Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.79
-0.2100-0.15%
Post-market: 144.070.2780+0.19%17:18 EDT
Volume:7.83M
Turnover:1.12B
Market Cap:354.75B
PE:112.97
High:144.15
Open:143.85
Low:142.32
Close:144.00
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.90
T/O Rate:0.32%
Dividend:3.36
Dividend Rate:2.34%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

Phanes Therapeutics: to Evaluate Spevatamig in Combination with Keytruda & Chemotherapy for Treatment of Biliary Tract Cancer

THOMSON REUTERS
·
Jul 21

Phanes Therapeutics: Expansion of Clinical Trial Collaboration and Supply Agreement with Merck

THOMSON REUTERS
·
Jul 21

Stocks Need Some Tech Magic to Kickstart Market Rally

Dow Jones
·
Jul 20

Palantir Stock Price Still Misses Its Cash Flow Strength

Simply Wall St.
·
Jul 20

UBS Remains a Buy on Merck KGaA (0O14)

TIPRANKS
·
Jul 20

Personalis Has Already Doubled—Is Merck About To Trigger Another Surge?

Smartkarma
·
Jul 20

What Comes After Merck's Keytruda? the Race for the Next Standard Cancer Treatment.

Dow Jones
·
Jul 20

Merck Animal Health Division's Inactivated Intradermal Immunization Vaccine for Porcine Mycoplasma Pneumonia Approved in China - Company Notice

THOMSON REUTERS
·
Jul 20

Movement Alert|Merck Rises 3.09% in Regular Trading, Oral PCSK9 Inhibitor Lipfendra Receives FDA Approval

Market Focus
·
Jul 17

July 2026's Top Stock Selections Estimated Below Fair Market Value

Simply Wall St.
·
Jul 17

Sector Update: Healthcare

MT Newswires Live
·
Jul 17

Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says

MT Newswires Live
·
Jul 16

Unitedhealth, Merck Share Gains Contribute to Dow's 166-point Jump

Dow Jones
·
Jul 16

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

TradingKey
·
Jul 16

Merck (MRK) Rises after FDA Clears First Oral PCSK9 Cholesterol Pill

TIPRANKS
·
Jul 16

Movement Alert|Merck Rises 3.09% in Regular Trading, Oral PCSK9 Inhibitor Lipfendra Wins FDA Approval

Market Focus
·
Jul 16

Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug

Reuters
·
Jul 16

Merck & Co Inc: List Price (wholesale Acquisition Cost) for Lipfendra Will be $10.50 Per Day, Based on a 30-day Supply

THOMSON REUTERS
·
Jul 16

Merck’s Lipfendra approved by FDA for adults with hypercholesterolemia

TIPRANKS
·
Jul 16

Merck Says FDA Approves Oral PCSK9 Inhibitor Lipfendra for Adults with High LDL-C

Reuters
·
Jul 16